share_log

HC Wainwright & Co. Upgrades Aerpio Pharmaceuticals to Buy, Announces $22 Price Target

Benzinga Real-time News ·  Jul 8, 2021 06:11

HC Wainwright & Co. analyst Robert Burns upgrades Aerpio Pharmaceuticals (NASDAQ:ARPO) from Neutral to Buy and announces $22 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment